Latest Insider Transactions at Organogenesis Holdings Inc. (ORGO)
This section provides a real-time view of insider transactions for Organogenesis Holdings Inc. (ORGO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Organogenesis Holdings Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Organogenesis Holdings Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 19
2025
|
Robert Cavorsi Vice President, Strategy |
BUY
Grant, award, or other acquisition
|
Direct |
61,705
+24.47%
|
-
|
|
Feb 19
2025
|
David Francisco Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
165,156
+22.8%
|
-
|
|
Feb 19
2025
|
Lori Freedman Chief Admin. and Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
162,047
+21.43%
|
-
|
|
Feb 19
2025
|
Brian Grow Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
183,067
+21.45%
|
-
|
|
Feb 19
2025
|
Antonio S. Montecalvo Vice President, Health Policy |
BUY
Grant, award, or other acquisition
|
Direct |
42,493
+17.77%
|
-
|
|
Feb 19
2025
|
Patrick Bilbo Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
184,136
+16.25%
|
-
|
|
Feb 19
2025
|
Arthur S Leibowitz Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,575
+17.29%
|
-
|
|
Feb 19
2025
|
Garrett Lustig Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,575
+39.19%
|
-
|
|
Feb 19
2025
|
Gilberto Quintero Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,575
+20.67%
|
-
|
|
Feb 19
2025
|
Jon L Giacomin Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,575
+20.5%
|
-
|
|
Feb 19
2025
|
Gary S. Gillheeney President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
708,215
+16.77%
|
-
|
|
Feb 19
2025
|
Michele Ilene Korfin Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,575
+20.67%
|
-
|
|
Feb 19
2025
|
Michael Joseph Driscoll Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,575
+20.53%
|
-
|
|
Feb 19
2025
|
Prathyusha Duraibabu Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,575
+20.01%
|
-
|
|
Feb 16
2025
|
Gary S. Gillheeney President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,123
-0.22%
|
$18,369
$3.7 P/Share
|
|
Feb 16
2025
|
Antonio S. Montecalvo Vice President, Health Policy |
SELL
Payment of exercise price or tax liability
|
Direct |
719
-0.46%
|
$2,157
$3.7 P/Share
|
|
Feb 16
2025
|
David Francisco Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
804
-0.2%
|
$2,412
$3.7 P/Share
|
|
Feb 16
2025
|
Lori Freedman Chief Admin. and Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
646
-0.15%
|
$1,938
$3.7 P/Share
|
|
Feb 16
2025
|
Patrick Bilbo Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
790
-0.1%
|
$2,370
$3.7 P/Share
|
|
Feb 16
2025
|
Brian Grow Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
656
-0.13%
|
$1,968
$3.7 P/Share
|
|
Feb 15
2025
|
Gary S. Gillheeney President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
225,963
-2.54%
|
$677,889
$3.7 P/Share
|
|
Feb 15
2025
|
Antonio S. Montecalvo Vice President, Health Policy |
SELL
Payment of exercise price or tax liability
|
Direct |
13,362
-2.7%
|
$40,086
$3.7 P/Share
|
|
Feb 15
2025
|
Robert Cavorsi Vice President, Strategy |
SELL
Payment of exercise price or tax liability
|
Direct |
11,008
-4.02%
|
$33,024
$3.7 P/Share
|
|
Feb 15
2025
|
David Francisco Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
34,253
-2.72%
|
$102,759
$3.7 P/Share
|
|
Feb 15
2025
|
Lori Freedman Chief Admin. and Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
36,478
-2.65%
|
$109,434
$3.7 P/Share
|
|
Feb 15
2025
|
Patrick Bilbo Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
43,366
-1.81%
|
$130,098
$3.7 P/Share
|
|
Feb 15
2025
|
Brian Grow Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
32,730
-2.13%
|
$98,190
$3.7 P/Share
|
|
Jan 09
2025
|
Alan A. Ades Director |
BUY
Bona fide gift
|
Direct |
12,803,890
+11.14%
|
-
|
|
Jan 09
2025
|
Alan A. Ades Director |
BUY
Bona fide gift
|
Indirect |
12,803,890
+11.14%
|
-
|
|
Jan 09
2025
|
Alan A. Ades Director |
SELL
Bona fide gift
|
Direct |
12,803,890
-11.14%
|
-
|
|
Dec 31
2024
|
Alan A. Ades Director |
BUY
Bona fide gift
|
Direct |
3,421,104
+3.24%
|
-
|
|
Dec 31
2024
|
Alan A. Ades Director |
BUY
Bona fide gift
|
Indirect |
3,421,104
+3.24%
|
-
|
|
Dec 31
2024
|
Alan A. Ades Director |
SELL
Bona fide gift
|
Direct |
3,421,104
-3.24%
|
-
|
|
Dec 16
2024
|
Gary S. Gillheeney President and CEO |
SELL
Open market or private sale
|
Direct |
5,585
-0.18%
|
$16,755
$3.49 P/Share
|
|
Dec 13
2024
|
Gary S. Gillheeney President and CEO |
SELL
Open market or private sale
|
Direct |
55,615
-1.79%
|
$166,845
$3.36 P/Share
|
|
Dec 12
2024
|
Gary S. Gillheeney President and CEO |
SELL
Open market or private sale
|
Direct |
43,359
-1.38%
|
$130,077
$3.55 P/Share
|
|
Dec 11
2024
|
Gary S. Gillheeney President and CEO |
SELL
Open market or private sale
|
Direct |
157,448
-4.77%
|
$472,344
$3.64 P/Share
|
|
Dec 10
2024
|
Gary S. Gillheeney President and CEO |
SELL
Open market or private sale
|
Direct |
58,525
-1.74%
|
$175,575
$3.64 P/Share
|
|
Dec 09
2024
|
Gary S. Gillheeney President and CEO |
SELL
Open market or private sale
|
Direct |
41,052
-1.21%
|
$123,156
$3.52 P/Share
|
|
Dec 06
2024
|
Gary S. Gillheeney President and CEO |
SELL
Open market or private sale
|
Direct |
18,416
-0.54%
|
$55,248
$3.65 P/Share
|
|
Dec 05
2024
|
Gary S. Gillheeney President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,067,245
+23.79%
|
$0
$0.99 P/Share
|
|
Nov 27
2024
|
Gn 2016 Family Trust U/A/D August 12, 2016 > 10% Shareholder |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,000,000
-0.97%
|
$4,000,000
$4.06 P/Share
|
|
Nov 12
2024
|
Albert Erani > 10% Shareholder |
SELL
Sale (or disposition) back to the issuer
|
Direct |
13,213,462
-3.9%
|
$39,640,386
$3.16 P/Share
|
|
Nov 12
2024
|
Albert Erani > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
1,630,000
-0.69%
|
$4,890,000
$3.16 P/Share
|
|
Jul 16
2024
|
Robert Cavorsi Vice President, Strategy |
SELL
Payment of exercise price or tax liability
|
Direct |
317
-0.23%
|
$951
$3.09 P/Share
|
|
Apr 01
2024
|
Gary S. Gillheeney President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,113
-0.43%
|
$20,226
$2.8 P/Share
|
|
Apr 01
2024
|
Antonio S. Montecalvo Vice President, Health Policy |
SELL
Payment of exercise price or tax liability
|
Direct |
1,752
-1.03%
|
$3,504
$2.8 P/Share
|
|
Apr 01
2024
|
Brian Grow Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,977
-0.38%
|
$3,954
$2.8 P/Share
|
|
Apr 01
2024
|
Lori Freedman Chief Admin. and Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,974
-0.42%
|
$3,948
$2.8 P/Share
|
|
Apr 01
2024
|
Patrick Bilbo Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,497
-0.31%
|
$4,994
$2.8 P/Share
|